Abstract: The invention provides a novel method of preparing a capture phase for detecting and/or quantifying a target biological entity, said capture phase including a biological ligand for the biological entity, said biological ligand being covalently bonded to an amphiphilic polymer and being immobilized on a solid support, the method being characterized in that the biological ligand is immobilized on the solid support by bringing the solid support into contact with a dispersion of micelles formed by a plurality of chains of the amphiphilic polymer, said micelles carrying a plurality of molecules of the biological ligand on the surface thereof. The invention also provides corresponding capture phases and associated detection methods and kits.

Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.

Abstract: Stroke is diagnosed in a subject by determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid taken from the subject.

Abstract: The present invention provides methods for the identification and use of diagnostic markers for differential diagnosis of diseases. In various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases that exhibit one or more similar or identical symptoms. Such methods and compositions can be used to provide assays and assay devices for use in determining the disease underlying one or more non-specific symptoms exhibited in a clinical setting.

Abstract: Stroke is diagnosed in a subject by determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid taken from the subject.

Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.

Abstract: The present invention provides a method of diagnosis of stroke or the possibility thereof in a subject suspected of suffering from stroke, comprising subjecting a sample of body fluid taken from the subject to mass spectrometry to determine a test amount of a polypeptide in the sample, wherein the polypeptide is differentially contained in the body fluid of stroke-affected subjects and non-stroke-affected subjects, and has a molecular weight in the range of from 3000 to 30000 Da; and determining whether the test amount is consistent with a diagnosis of stroke. The test amount can also be used to determine the type of stroke that is diagnosed, in particular whether it is of the ischemic or hemorrhagic type. The invention also provides use of the polypeptides for diagnostic, prognostic and therapeutic applications.

Abstract: The invention concerns a nucleotide sequence coding for a modified protein of interest, said protein of interest having, after purification and immobilization, at least the same biological activity as the native protein of interest and being directly usable, said sequence comprising at least a gene coding for said protein of interest, a nucleotide fragment, called polyK, coding for a succession of at least six lysine residues, and a nucleotide fragment, called polyH, coding for a succession of at least six histidine residues; a vector comprising such a sequence; and a method for obtaining a purifiable and immobilized modified protein of interest.